Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

The drug attaches to a protein called programmed death receptor-1 (PD-1). Keytruda blocks the interaction of this protein with another protein called programmed death ligand-1 (PD-L1). The ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have ... its last remaining late-stage trial of the PD-1 inhibitor in prostate cancer. The decision comes ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

TX an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, in ...